Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Larimar Therapeutics, Inc. | zfgn-ex321_9.htm |
| EX-31.2 - EX-31.2 - Larimar Therapeutics, Inc. | zfgn-ex312_8.htm |
| EX-31.1 - EX-31.1 - Larimar Therapeutics, Inc. | zfgn-ex311_6.htm |
| EX-21.1 - EX-21.1 - Larimar Therapeutics, Inc. | zfgn-ex211_81.htm |
| EX-10.35 - EX-10.35 - Larimar Therapeutics, Inc. | zfgn-ex1035_169.htm |
| EX-10.28 - EX-10.28 - Larimar Therapeutics, Inc. | zfgn-ex1028_415.htm |
| EX-4.3 - EX-4.3 - Larimar Therapeutics, Inc. | zfgn-ex43_80.htm |
| 10-K - 10-K - Larimar Therapeutics, Inc. | zfgn-10k_20191231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-219834 and 333-228328) and Form S-8 (Nos. 333-210216, 333-196900, 333-204931, 333-216602, 333-22356, 333-228326, 333-230291, and 333-234579) of Zafgen, Inc. of our report dated March 5, 2020 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 5, 2020